MR
Meghana Rajen Shah
About Meghana Rajen Shah
Data last updated:
Meghana Rajen Shah is a Director at Raptim Research Private Limited (since 2024) and Director at Nova Chemdrugs Private Limited (since 2023). The companies operate in Life Sciences and Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹149 Cr; the largest is Raptim Research Private Limited at ₹146 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Raptim Research Private Limited U73100MH2002PTC136230 | Director | 19 Feb 2024 | 2002 | ₹146 Cr (FY 2025) | Active |
 Nova Chemdrugs Private Limited U24232MH2001PTC108616 | Director | 29 Nov 2023 | 2001 | ₹3.09 Cr (FY 2025) | Active |
Board colleagues of Meghana Rajen Shah
| Name | DIN | Company | Designation |
|---|---|---|---|
| Rajen Dhirubhai Shah | 00051964 | Raptim Research Private Limited , Nova Chemdrugs Private Limited | Whole-Time Director |
| Viraj Dhirubhai Shah | 02579881 | Raptim Research Private Limited , Nova Chemdrugs Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Meghana Rajen Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Meghana Rajen Shah
Meghana Rajen Shah currently holds 2 directorships: Raptim Research Private Limited (Director, since 19 Feb 2024, revenue ₹146 Cr (FY 2025)); Nova Chemdrugs Private Limited (Director, since 29 Nov 2023, revenue ₹3.09 Cr (FY 2025)).
Meghana Rajen Shah was first appointed on 29 Nov 2023 as Director at Nova Chemdrugs Private Limited. The most recent appointment on record is 19 Feb 2024 at Raptim Research Private Limited.
The 2 current companies of Meghana Rajen Shah that report revenue have a combined latest revenue of ₹149 Cr: Raptim Research Private Limited ₹146 Cr (FY 2025); Nova Chemdrugs Private Limited ₹3.09 Cr (FY 2025).
The current boards of Meghana Rajen Shah's companies include Rajen Dhirubhai Shah (Raptim Research Private Limited), Viraj Dhirubhai Shah (Raptim Research Private Limited).